, Lancero M, Narvaez A, McGrath MS: MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2006, 179:873. 23. Dawson J, Miltz W, Mir AK, Wiessner C: Targeting monocyte chemoattractant protein-1 signalling in disease. Specialist Opin Ther Targets 2003, 7:358. 24. Roebuck KA, Carpenter LR, Lakshminarayanan V, Web page SM, Moy JN, Thomas LL: Stimulus-specific regulation of chemokine expression includes differential activation with the redox-responsive transcription components AP-1 and NF-B. J Leukoc Biol 1999, 65:29198. 25. Allavena P, Bianchi G, Zhou D, van Damme J, J ek P, Sozzani S, Mantovani A: Induction of organic killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994, 24:3233236. 26. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT: Post-ischemic brain damage: pathophysiology and part of inflammatory mediators. FEBS J 2009, 276:136. 27. Hinojosa AE, Garcia-Bueno B, Leza JC, Madrigal JL: CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation 2011, 8:77. 28. Lee EO, Park HJ, Kang JL, Kim HS, Chong YH: Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression through inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures. J Neurochem 2010, 112:1477487.Lumasiran 29.Anti-Mouse IL-10 Antibody Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivis k P, Tucky B, et al: Modulating CCR2 and CCL2 at the blood rain barrier: relevance for many sclerosis pathogenesis.PMID:26644518 Brain 2006, 129:21223. 30. Semple BD, Bye N, Rancan M, Ziebell JM, Morganti-Kossmann MC: Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from serious TBI patients and CCL2-/- mice. J Cereb Blood Flow Metab 2010, 30:76982.31. Tanabe S, Heesen M, Berman MA, Fischer MB, Yoshizawa I, Luo Y, Dorf ME: Murine astrocytes express a functional chemokine receptor. J Neurosci 1997, 17:6522528. 32. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A: Enhanced levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol 2009, 16:77174. 33. Philips T, Robberecht W: Neuroinflammation in amyotrophic lateral sclerosis: part of glial activation in motor neuron disease. Lancet Neurol 2011, 10:25363. 34. Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe N, Ohyagi Y, Kira J: CSF chemokine alterations connected towards the clinical course of amyotrophic lateral sclerosis. J uroimmunol 2010, 222:761. 35. Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, et al: Expression of various functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 2000, 97:59100. 36. Meng SZ, Oka A, Takashima S: Developmental expressison of monocyte chemoattractant protein-1 within the human cerebellum and brainstem. Brain Dev 1999, 21:305. 37. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyanf G, et al: Modulating inflammatory monocytes having a exceptional microRNA gene signature ameliorates murine ALS. J Clin Invest 2012, 122:3063087. 38. Sargsyan SA, Blackburn DJ, Barber SC, Monk PN, Shaw PJ: Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1. NeuroReport 2009, 20:1450455. 39. Semple BD, Kossmann T, Morganti-Kossmann MC: Function of chemokines in CNS health and pathology: a concentrate on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 2010, 30:45973. 40. Croitoru-Lamoury J, Guillemin GJ, Bou.